Developer docs
API playgroundTry for free, no card

Search company profiles

Ectosense

Full company profile

uuid0009dg4

Namestring
Ectosense
Websiteurl
ectosense.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Ectosense is a Belgium-based medtech company founded in 2015 that developed the NightOwl Home Sleep Test, a consumer-grade device enabling patients to diagnose obstructive sleep apnea without attending a clinic or sleep center. The product consists of the NightOwl Sensor hardware and a NightOwl Companion mobile application used by patients and healthcare providers, with the sensor transmitting data for clinical review. Ectosense operated as a small, sub-ten-person R&D and product company headquartered in Rotselaar, Belgium, with Ciaran McCourt serving as CEO and early backing from imec.istart (2015) and Saffelberg Investments (2018).

The company monetized the NightOwl device through one-time per-unit sales; following ResMed's April 2025 acquisition and subsequent relaunch, the product is positioned at approximately $140 per unit and distributed through ResMed's global healthcare provider channel across North America, Europe, Australia and New Zealand, and Asia. Ectosense's strategic target is the estimated 936 million people worldwide with undiagnosed sleep apnea, with explicit commercial emphasis on GLP-1 weight-loss drug patients, a cohort reported by ResMed to convert to CPAP therapy at an 11% higher rate than the general population.

Post-acquisition, Ectosense no longer operates as an independent entity; the NightOwl brand, technology, FDA-cleared IP, and product line have been integrated into ResMed's sleep and respiratory care portfolio, with regional patient and HCP support operations handling inbound inquiries under ResMed email domains. Independent revenue, headcount growth, and product pipeline metrics are no longer separately disclosed.

Short descriptiontext

Ectosense is a Belgium-based medtech company that developed the NightOwl home sleep test device and companion app for at-home sleep apnea diagnosis. It was acquired by ResMed in 2025, after which the product was relaunched at approximately $140 per unit and distributed globally through ResMed's healthcare provider channel.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLeuven, Belgium
HQ citystring
Leuven
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
home sleep testing, sleep apnea diagnosis, sleep medicine devices, respiratory diagnostics, medical technology
Industry1 code
PRIMARYHLAHAGAB
Sleep Diagnostics & Monitoring (PSG/Home Sleep Testing, Actigraphy)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Sleep Diagnostics
No data
Revenue model1 record
1Home Sleep Test Device Sales
TypeOne Time License
Description

Ectosense developed and sold the NightOwl home sleep testing device. The company was subsequently acquired by Resmed, who now commercializes the product at approximately $140 per unit.

insights.citeline.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales
Pricing details1 tier
1NightOwl Home Sleep Test device
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Priced at approximately $140 per unit

insights.citeline.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Ectosense developed and sold the NightOwl, a home sleep testing device for diagnosing sleep apnea. The product enables patients to conduct sleep apnea diagnosis without visiting a clinic or sleep center. Ectosense was acquired by ResMed, which relaunched the NightOwl device in April 2025 at approximately $140 per unit as part of its strategy to reduce diagnostic bottlenecks and address the estimated 936 million people worldwide with undiagnosed sleep apnea.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Resmed reports that GLP-1 weight loss drug users show 11% higher CPAP adoption rates and higher long-term mask purchasing compared to non-GLP-1 patients, indicating higher diagnosis-to-treatment conversion
Product overview1 text field

Ectosense's primary product was NightOwl, a home sleep test device for diagnosing sleep apnea. The company was acquired by ResMed, which relaunched NightOwl in April 2025 as part of its diagnostic strategy. The offering consists of the NightOwl Sensor hardware and the companion NightOwl Companion app for patient and healthcare provider interaction.

Product and service2 records
1NightOwl Home Sleep Test
CategorySleep Diagnostics Device
Description

A home sleep test device for diagnosing sleep apnea that enables patients to conduct diagnosis without visiting a clinic or sleep center. Acquired by ResMed through Ectosense and relaunched in April 2025. Designed for healthcare providers and patients as part of the sleep apnea diagnostic pathway.

2NightOwl Companion App
CategoryCompanion Software
Description

Mobile application paired with the NightOwl Sensor for sleep testing. Available for patients and healthcare providers with regional support contacts across North America, Europe, Australia/New Zealand, and Asia.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeRegional player
Description

China-based manufacturer of respiratory and sleep care devices including home sleep testing and CPAP products. Comparable regional player in the sleep diagnostic and therapy category with overlapping product set.

TypeBroad incumbent
Description

Global incumbent in sleep apnea and respiratory care with both diagnostic (Alice PSG) and therapy (CPAP) portfolios. Comparable as a broad incumbent whose diagnostic offering overlaps with NightOwl's category.

TypeEmerging player
Description

Apple Watch has received FDA clearance for sleep apnea notifications, positioning the consumer wearable as an emerging low-friction screening alternative to dedicated home sleep tests like NightOwl.

TypeEmerging player
Description

Maker of connected health devices including sleep tracking mats (Withings Sleep Analyzer) that screen for sleep apnea, representing a consumer-grade alternative to clinical home sleep tests like NightOwl.

TypeDirect peer
Description

Acquired by ZOLL Medical/Itamar Medical, maker of the WatchPAT home sleep apnea test — a direct competitor to NightOwl in the at-home sleep diagnostic device category, with similar FDA-cleared disposable-sensor architecture.

TypeOthers
Description

Acquirer of Ectosense and now the commercial vehicle for NightOwl; while not a peer in the competitive sense, ResMed is the most relevant comparable for assessing scale, distribution, and downstream CPAP economics tied to NightOwl.

TypeBroad incumbent
Description

Major respiratory care and sleep apnea therapy manufacturer with growing diagnostic-adjacent offerings. Relevant as a broad incumbent operating in the same downstream sleep apnea care pathway.

TypeDirect peer
Description

Provider of home sleep testing systems (SleepView, BioNomadix) for sleep apnea screening. Competes head-to-head with NightOwl in the prescription home sleep test market for healthcare providers.

TypeEmerging player
Description

Oura Ring has introduced sleep apnea detection features, positioning it as an emerging consumer wearable competitor that could compete with dedicated home sleep testing devices for screening-stage demand.

TypeDirect peer
Description

Manufactures the Nox T3 and Nox A1 home sleep testing/PSG systems used by sleep specialists and research labs. Directly comparable as a home sleep diagnostic device vendor serving the same clinical pathway as NightOwl.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ectosense

Sleep Diagnosticsectosense.com

Ectosense is a Belgium-based medtech company that developed the NightOwl home sleep test device and companion app for at-home sleep apnea diagnosis. It was acquired by ResMed in 2025, after which the product was relaunched at approximately $140 per unit and distributed globally through ResMed's healthcare provider channel.

What Ectosense does

Ectosense is a Belgium-based medtech company founded in 2015 that developed the NightOwl Home Sleep Test, a consumer-grade device enabling patients to diagnose obstructive sleep apnea without attending a clinic or sleep center. The product consists of the NightOwl Sensor hardware and a NightOwl Companion mobile application used by patients and healthcare providers, with the sensor transmitting data for clinical review. Ectosense operated as a small, sub-ten-person R&D and product company headquartered in Rotselaar, Belgium, with Ciaran McCourt serving as CEO and early backing from imec.istart (2015) and Saffelberg Investments (2018).

The company monetized the NightOwl device through one-time per-unit sales; following ResMed's April 2025 acquisition and subsequent relaunch, the product is positioned at approximately $140 per unit and distributed through ResMed's global healthcare provider channel across North America, Europe, Australia and New Zealand, and Asia. Ectosense's strategic target is the estimated 936 million people worldwide with undiagnosed sleep apnea, with explicit commercial emphasis on GLP-1 weight-loss drug patients, a cohort reported by ResMed to convert to CPAP therapy at an 11% higher rate than the general population.

Post-acquisition, Ectosense no longer operates as an independent entity; the NightOwl brand, technology, FDA-cleared IP, and product line have been integrated into ResMed's sleep and respiratory care portfolio, with regional patient and HCP support operations handling inbound inquiries under ResMed email domains. Independent revenue, headcount growth, and product pipeline metrics are no longer separately disclosed.

Ectosense firmographics

Firmographics
Name
Ectosense
Website
https://ectosense.com
Company type
Private
Founded year
2015
Operating status
Acquired
Headcount range
11–50 employees
Short description
Ectosense is a Belgium-based medtech company that developed the NightOwl home sleep test device and companion app for at-home sleep apnea diagnosis. It was acquired by ResMed in 2025, after which the product was relaunched at approximately $140 per unit and distributed globally through ResMed's healthcare provider channel.
Ownership category
akta.pro rank

Ectosense industry classification

Industry
Product category
Sleep Diagnostics
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAGAB
Sleep Diagnostics & Monitoring (PSG/Home Sleep Testing, Actigraphy)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices

Keywords

  • Home sleep testing
  • Sleep apnea diagnosis
  • Sleep medicine devices
  • Respiratory diagnostics
  • Medical technology

Where Ectosense is headquartered

Location

Headquarters

HQ city
Leuven
HQ country
Belgium
HQ region
Europe

Markets served

Ectosense business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Home Sleep Test Device Sales: Ectosense developed and sold the NightOwl home sleep testing device. The company was subsequently acquired by Resmed, who now commercializes the product at approximately $140 per unit.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goNightOwl Home Sleep Test device

Distribution channels2 records

Marketing channels2 records

Ectosense product offering

Product offering

Core offering

Ectosense developed and sold the NightOwl, a home sleep testing device for diagnosing sleep apnea. The product enables patients to conduct sleep apnea diagnosis without visiting a clinic or sleep center. Ectosense was acquired by ResMed, which relaunched the NightOwl device in April 2025 at approximately $140 per unit as part of its strategy to reduce diagnostic bottlenecks and address the estimated 936 million people worldwide with undiagnosed sleep apnea.

Product overview

Ectosense's primary product was NightOwl, a home sleep test device for diagnosing sleep apnea. The company was acquired by ResMed, which relaunched NightOwl in April 2025 as part of its diagnostic strategy. The offering consists of the NightOwl Sensor hardware and the companion NightOwl Companion app for patient and healthcare provider interaction.

Differentiator

Problem solved

Functional benefit

Products and services

  • NightOwl Home Sleep Test A home sleep test device for diagnosing sleep apnea that enables patients to conduct diagnosis without visiting a clinic or sleep center. Acquired by ResMed through Ectosense and relaunched in April 2025. Designed for healthcare providers and patients as part of the sleep apnea diagnostic pathway.
  • NightOwl Companion App Mobile application paired with the NightOwl Sensor for sleep testing. Available for patients and healthcare providers with regional support contacts across North America, Europe, Australia/New Zealand, and Asia.

Quantifiable outcome

  • Resmed reports that GLP-1 weight loss drug users show 11% higher CPAP adoption rates and higher long-term mask purchasing compared to non-GLP-1 patients, indicating higher diagnosis-to-treatment conversion

Companies that use Ectosense

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Ectosense technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Ectosense partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Ectosense competitors and assessment

Company assessment

Regional players

  • BMC Medical: China-based manufacturer of respiratory and sleep care devices including home sleep testing and CPAP products. Comparable regional player in the sleep diagnostic and therapy category with overlapping product set.

Broad incumbents

  • Philips Respironics: Global incumbent in sleep apnea and respiratory care with both diagnostic (Alice PSG) and therapy (CPAP) portfolios. Comparable as a broad incumbent whose diagnostic offering overlaps with NightOwl's category.
  • Fisher & Paykel Healthcare: Major respiratory care and sleep apnea therapy manufacturer with growing diagnostic-adjacent offerings. Relevant as a broad incumbent operating in the same downstream sleep apnea care pathway.

Emerging players

  • Apple: Apple Watch has received FDA clearance for sleep apnea notifications, positioning the consumer wearable as an emerging low-friction screening alternative to dedicated home sleep tests like NightOwl.
  • Withings: Maker of connected health devices including sleep tracking mats (Withings Sleep Analyzer) that screen for sleep apnea, representing a consumer-grade alternative to clinical home sleep tests like NightOwl.
  • Oura: Oura Ring has introduced sleep apnea detection features, positioning it as an emerging consumer wearable competitor that could compete with dedicated home sleep testing devices for screening-stage demand.

Direct peers

  • Itamar Medical: Acquired by ZOLL Medical/Itamar Medical, maker of the WatchPAT home sleep apnea test — a direct competitor to NightOwl in the at-home sleep diagnostic device category, with similar FDA-cleared disposable-sensor architecture.
  • CleveMed: Provider of home sleep testing systems (SleepView, BioNomadix) for sleep apnea screening. Competes head-to-head with NightOwl in the prescription home sleep test market for healthcare providers.
  • Nox Medical: Manufactures the Nox T3 and Nox A1 home sleep testing/PSG systems used by sleep specialists and research labs. Directly comparable as a home sleep diagnostic device vendor serving the same clinical pathway as NightOwl.

Others

  • ResMed: Acquirer of Ectosense and now the commercial vehicle for NightOwl; while not a peer in the competitive sense, ResMed is the most relevant comparable for assessing scale, distribution, and downstream CPAP economics tied to NightOwl.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Ectosense financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ectosense leadership team

Management profile

Number of profiles

Profiles1 record

Ectosense funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ectosense M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ectosense

What does Ectosense do?

Ectosense developed and sold the NightOwl, a home sleep testing device for diagnosing sleep apnea. The product enables patients to conduct sleep apnea diagnosis without visiting a clinic or sleep center. Ectosense was acquired by ResMed, which relaunched the NightOwl device in April 2025 at approximately $140 per unit as part of its strategy to reduce diagnostic bottlenecks and address the estimated 936 million people worldwide with undiagnosed sleep apnea.

Is Ectosense a public or private company?

Ectosense is a private company. It is classified as corporate owned and is currently acquired.

When was Ectosense founded?

Ectosense was founded in 2015. It employs 11 to 50 people.

Where is Ectosense based?

Ectosense is headquartered in Leuven, Belgium, in the Europe region.

How does Ectosense make money?

One revenue line is on record: home Sleep Test Device Sales.

Who are Ectosense's main competitors?

BMC Medical is listed as a regional player. Broad incumbents are Philips Respironics and Fisher & Paykel Healthcare. Emerging players are Apple, Withings and Oura. Direct peers are Itamar Medical, CleveMed and Nox Medical. ResMed is listed as an others.

Does Ectosense have an API?

No public API is recorded for Ectosense.

What industry is Ectosense in?

Ectosense's product category is Sleep Diagnostics. Its primary akta.pro industry code is HLAHAGAB, Sleep Diagnostics & Monitoring (PSG/Home Sleep Testing, Actigraphy). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals